Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorundrostat - Mineralys Therapeutics

Drug Profile

Lorundrostat - Mineralys Therapeutics

Alternative Names: MLS-101; MT-4129

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Mineralys Therapeutics; Mitsubishi Tanabe Pharma Corporation
  • Class Acetamides; Amides; Antihypertensives; Benzene derivatives; Cardiovascular therapies; Cyclohexylamines; Small molecules; Triazines
  • Mechanism of Action Aldosterone synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypertension
  • Phase II Renal failure
  • No development reported Cardiovascular disorders

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in Netherlands (PO)
  • 21 Mar 2024 Mineralys Therapeutics plans a phase II Explore-CKD proof of concept trial for chronic kidney disease (Combination therapy, Late-stage disease) (renal failure) in second half of 2023 (PO)
  • 14 Dec 2023 Phase-II clinical trials in Renal failure (Combination therapy) in USA (PO) (NCT06150924)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top